Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This clinical trial is studying body mass index in younger patients receiving
prednisone/prednisolone, vincristine, daunorubicin, and pegaspargase for high-risk acute
lymphoblastic leukemia. Studying samples of blood from patients with cancer in the laboratory
may help doctors learn more about the affect of body mass index on the way anticancer drugs
work in the body. It may also help doctors predict how patients will respond to treatment